【レポートの概要（一部）】
PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
PART 05: Overview of cancer immunotherapies
• Epidemiology
• Spending on cancer
• Cost of cancer treatment
• Reimbursement policies
• Economic burden of cancer
• Orphan drug designation and regulatory approvals
PART 06: Pipeline portfolio
• Anticipated number of products with single and multi-indications by 2020
PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 08: Market segmentation by type
• Cancer monoclonal antibodies
• Clinical trials of cancer monoclonal antibodies
• Immune checkpoint inhibitors
• Cancer vaccines
• Non-specific immunotherapies
• Global cancer monoclonal antibodies market
• Global cancer vaccines market
• Global immune checkpoint inhibitors market
• Global non-specific immunotherapies market
PART 09: Geographical segmentation
• Global cancer immunotherapies market by geography 2015-2020
• Cancer immunotherapies market in Americas
• Cancer immunotherapies market in EMEA
• Cancer immunotherapies market in APAC
PART 10: Market drivers
• Increase in prevalence of cancers
• Increase in demand for cancer monoclonal antibodies
• Patient assistance programs
• Promising pipeline
PART 11: Impact of drivers
PART 12: Market challenges
• Patent expiry of top-selling drugs
• Poor diagnosis and screening
• High developmental costs
• Risk of side-effects
• Stringent regulations
PART 13: Impact of drivers and challenges
PART 14: Market trends
• Increase in cancer awareness
• Emergence of targeted and combination therapies
• Emergence of biosimilars
• Strategic alliances
PART 15: Vendor landscape
• Competitive scenario
• Market share analysis 2015
• Amgen
• Bristol-Myers Squibb
• F. Hoffmann-La Roche
• GlaxoSmithKline
• Merck
• Takeda Pharmaceuticals1
• Other prominent vendors
PART 16: Appendix
• List of abbreviations
PART 17: Explore Technavio
[List of Exhibits]
Exhibit 01: Product offerings
Exhibit 02: Cancer immunotherapies in global cancer drugs market
Exhibit 03: Global incidence of cancer by type 2015
Exhibit 04: Global mortality by cancer type 2015
Exhibit 05: Estimated numbers of male and female cancer survivors by age in US 2014
Exhibit 06: Spending on cancer by distribution channels 2013
Exhibit 07: Annual treatment cost per patient for cancer immunotherapies 2014
Exhibit 08: Average cost of surgeries associated with cancer ($ millions) 2014
Exhibit 09: National reimbursement of cancer drugs by countries 2014
Exhibit 10: US FDA Orphan drug designations and approvals for cancer immunotherapies
Exhibit 11: EU orphan drug designations and approvals for cancer immunotherapies
Exhibit 12: Key events in cancer immunotherapies, discovery, and approvals
Exhibit 13: Timeline of some cancer immunotherapies
Exhibit 14: Phase III pipeline molecules for global cancer monoclonal antibodies market
Exhibit 15: Phase II pipeline molecules for global cancer monoclonal antibodies market
Exhibit 16: Phase I pipeline molecules for global cancer monoclonal antibodies market
Exhibit 17: Pipeline molecules for global immune checkpoint inhibitors market
Exhibit 18: Phase III pipeline molecules for global cancer vaccines market
Exhibit 19: Near-launch immuno-oncology pipeline assets
Exhibit 20: Global cancer immunotherapies market 2015-2020 ($ billions)
Exhibit 21: Factors influencing global cancer immunotherapies market
Exhibit 22: Five forces analysis
Exhibit 23: Global cancer immunotherapies market by type 2015
Exhibit 24: Timeline for approvals of cancer monoclonal antibodies by US FDA
Exhibit 25: Clinical trials of cancer monoclonal antibodies by development phase
Exhibit 26: Status of clinical trials of cancer monoclonal antibodies
Exhibit 27: Global cancer immunotherapies market by type of cancer immunotherapies 2015
Exhibit 28: Global cancer immunotherapies market by type of cancer immunotherapies 2015-2020 ($ billions)
Exhibit 29: Global cancer monoclonal antibodies market 2015-2020 ($ billions)
Exhibit 30: Key drivers and challenges of global cancer monoclonal antibodies market
Exhibit 31: Global cancer vaccines market 2015-2020 ($ billions)
Exhibit 32: Global cancer vaccines market by application 2015
Exhibit 33: Key drivers and challenges of global cancer vaccines market
Exhibit 34: Global immune checkpoint inhibitors market 2015-2020 ($ billions)
Exhibit 35: Key drivers and challenges for global immune checkpoint inhibitors market
Exhibit 36: Global non-specific immunotherapies market 2015-2020 ($ billions)
Exhibit 37: Global cancer immunotherapies market by geography 2015
Exhibit 38: Global cancer immunotherapies market revenue by geography 2015-2020 ($ billions)
Exhibit 39: Cancer immunotherapies market in Americas 2015-2020 ($ billions)
Exhibit 40: Cancer immunotherapies market in EMEA 2015-2020 ($ billions)
Exhibit 41: Cancer immunotherapies market in APAC 2015-2020 ($ billions)
Exhibit 42: Global incidence of cancer 2015 and 2020 in millions
Exhibit 43: Impact of drivers
Exhibit 44: Patent expiries of major cancer monoclonal antibodies by 2020
Exhibit 45: Impact of drivers and challenges
Exhibit 46: Expected combination regimen launches in oncology
Exhibit 47: Top cancer immunotherapies based on sales 2014 ($ billions)
Exhibit 48: YoY Sales comparison of top drugs 2011-2014 ($ billions)
Exhibit 49: Cancer immunotherapy companies by origin country
Exhibit 50: Amgen: YoY growth and revenue generated from net product sales of Xgeva 2011-2014 ($ millions)
Exhibit 51: Amgen: YoY growth and revenue generated from net product sales of Prolia 2011-2014 ($ millions)
Exhibit 52: Amgen: YoY growth and revenue generated from net product sales of Vectibix worldwide excluding Japan 2011-2014 ($ millions)
Exhibit 53: Amgen: YoY growth and revenue of Vectibix in US 2012-2014 ($ millions)
Exhibit 54: Amgen: YoY growth and revenue of Vectibix in ROW 2012-2014 ($ millions)
Exhibit 55: Amgen: Key takeaways
Exhibit 56: Bristol-Myers Squibb: Segmentation by revenue 2014
Exhibit 57: Bristol-Myers Squibb: Revenue of oncology products by category 2014
Exhibit 58: Bristol-Myers Squibb: YoY growth and revenue generated from net product sales of Yervoy 2011-2014 ($ millions)
Exhibit 59: Bristol-Myers Squibb: YoY growth and revenue of Erbitux in US, Canada, and Japan 2010-2014 ($ millions)
Exhibit 60: Bristol-Myers Squibb: Key takeaways
Exhibit 61: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of MabThera/Rituxan 2011-2014 ($ billions)
Exhibit 62: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Avastin 2011-2014 ($ billions)
Exhibit 63: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Herceptin 2011-2014 ($ billions)
Exhibit 64: F. Hoffmann-La Roche: YoY growth and revenue of Herceptin in US 2013-2014 ($ billions)
Exhibit 65: F. Hoffmann-La Roche: YoY growth and revenue of Herceptin in EU 2013-2014 ($ billions)
Exhibit 66: F. Hoffmann-La Roche: YoY growth and revenue of Herceptin in Japan 2013-2014 ($ millions)
Exhibit 67: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Perjeta 2012-2014 ($ millions)
Exhibit 68: F. Hoffmann-La Roche: Revenue generated from net product sales of Kadcyla 2013-2014 ($ millions)
Exhibit 69: F. Hoffmann-La Roche: Key takeaways
Exhibit 70: GlaxoSmithKline: YOY growth and revenue of Arzerra 2012-2014 ($ millions)3
Exhibit 71: GlaxoSmithKline: YOY growth and revenue of Cervarix 2012-2014 ($ millions)3
Exhibit 72: GlaxoSmithKline: Key takeaways
Exhibit 73: Merck: YoY growth and revenue of Gardasil 2012-2014 ($ billions)6
Exhibit 74: Merck: YoY growth and revenue generated from net product sales of Erbitux, excluding US, Canada, and Japan 2011-2014 ($ billions
Exhibit 75: Merck: YOY growth and revenue of Erbitux in Europe 2012-2014 ($ millions)
Exhibit 76: Merck: YOY growth and revenue of Erbitux in emerging markets 2012-2014 ($ millions)
Exhibit 77: Merck: YOY growth and revenue of Erbitux in ROW 2012-2014 ($ millions)
Exhibit 78: Merck: Region-wise revenues of Erbitux 2012-2014 ($ millions)
Exhibit 79: Merck: Key takeaways
Exhibit 80: Takeda Pharmaceuticals: YoY growth and revenue generated from net product sales of Adcetris ($ millions)
Exhibit 81: Takeda Pharmaceuticals: YoY growth and revenue of Vectibix in Japan ($ millions)
Exhibit 82: Takeda Pharmaceuticals: Key takeaways
【レポート販売概要】
■ タイトル：がん免疫療法の世界市場：モノクローナル抗体、免疫チェックポイント阻害薬、がんワクチン■ 英文：Global Cancer Immunotherapies Market 2016-2020
■ 発行日：2016年4月27日
■ 調査会社：Technavio
■ 商品コード：IRTNTR8400
■ 調査対象地域：グローバル
- Safinamide (パーキンソン病)：医薬品市場予測及び分析（～2022）Safinamide (Parkinson’s Disease) - Forecast and Market Analysis to 2022 Summary Parkinson’s disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson’s disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly …
- 低侵襲医療機器の世界市場：携帯式医療機器、ガイディングデバイス、インフレーションデバイス、補助機器、カッター器具The global MIS instrument market is segmented by product, application, and region. On the basis of products, the MIS instrument market is segmented into handheld instruments, cutter instruments, inflation systems, guiding devices, and auxiliary instruments. Among products, guiding devices are estimated to be the fastest-growing segment owing to the increasing demand of guiding catheters and guidew …
- 世界のシリコンエッチングシステム市場：Global Silicon Etching Systems Market 2014-2018TechNavio's analysts forecast the Global Silicon Etching Systems market to grow at a CAGR of 3.59 percent over the period 2013-2018. One of the key factors contributing to this market growth is the rising demand for smartphones and tablets. The Global Silicon Etching Systems market has also been witnessing the emergence of product miniaturization. However, the cyclical nature of the Semiconductor …
- 世界のIVD製品及びテスト市場（2012-2016）TechNavio's analysts forecast the Global In Vitro Diagnostics (IVD) Products and Test market to grow at a CAGR of 4.33 percent over the period 2012-2016. One of the key factors contributing to this market growth is the significant growth of the IVD market in emerging countries. The market has also been witnessing a significant increase in the number of acquisitions of small and medium companies. H …
- インスリン非依存型糖尿病治療薬の世界市場2018-2022About Non-insulin Diabetes Therapeutics Non-insulin diabetes therapeutics are mostly administered orally and prescribed when diet and exercise are insufficient to control elevated blood glucose levels. Technavio’s analysts forecast the global non-insulin diabetes therapeutics market to grow at a CAGR of 11.37% during the period 2018-2022. Covered in this report The report covers the present scenar …
- 非増殖性糖尿病性網膜症(NPDR)：グローバル臨床試験動向（2014年上半期）Non-Proliferative Diabetic Retinopathy (NPDR) Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Non-Proliferative Diabetic Retinopathy (NPDR) Global Clinical Trials Review, H1, 2014" provides data on the Non-Proliferative Diabetic Retinopathy (NPDR) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Non …
- 加工チーズの世界市場2017-2021About Processed CheeseThe global cheese market is expected to show moderate growth during the forecast period as cheese is an important ingredient for a host of fast foods such as burger, sandwich, hotdog, and pizza. Customer segments such as affluent customers, children, teenagers, and mainstream households have become the focus for cheese manufacturers. As protein is an essential nutrient that c …
- リチウムイオン電池の世界市場2015-2019About Li-ion Battery A li-ion battery is a rechargeable battery with the highest electrochemical potential. A positive terminal, negative terminal, and an electrolyte between the terminals constitute the main parts of the battery. Li-ion moves from the anode (made up of lithium cobalt oxide) to the cathode (made up of carbon or graphite) during charging and vice-versa during discharging. Some bene …
- ファブリックフィルターの世界市場予測（～2024年）Stringent regulations related to the treatment of industrial waste are driving the overall fabric filters market.The fabric filters market size is expected to grow from USD 2.3 billion in 2019 to USD 3.2 billion by 2024, at a Compound Annual Growth Rate (CAGR) of 6.4% during the forecast period. The fabric filters market is driven by various factors such as stringent regulations related to treatme …
- ウェアラブル拡張現実に関する規制と方針（Regulation and Policy for Wearable Augmented Reality）Progress in wearable technologies for monitoring is driven by the same factors that were behind the transition from desktop computing and communication tools to portable devices providing processing and ubiquitous connectivity. These drivers include substantive changes in key social and economic factors. This transition is fuelled by the enormous technical advances in microelectronics and communic …
- シリコーンの世界市場：タイプ別（エラストマー、流体、樹脂、ゲル、その他）、エンドユーザー別（建築、建設、輸送、パーソナルケア、消費財、エネルギー、電気、電子、紙、繊維、その他）The global silicone market was valued at $18.2 billion in 2018, and is projected to reach $91.4 billion by 2026, growing at a CAGR of 22.5% from 2019 to 2026. Silicone are polymers that are made up of siloxane. Siloxane is a chain of alternating silicon and oxygen atoms combined with carbon or hydrogen. It is a versatile material, owing to its exceptional chemical & mechanical properties, due to w …
- 世界の計装用バルブ及び継手市場：材料別、製品別（バルブ、継手、アクチュエーター）、産業別（半導体、石油＆ガス、食品＆飲料、化学薬品、ヘルスケア、パルプ＆紙、エネルギー＆電力）、地域別“Instrumentation valves and fittings market to grow at 3.0% CAGR from 2019 to 2025” The global instrumentation valves and fittings market size is expected to grow from USD 3.2 billion in 2019 to USD 3.9 billion by 2025, at a CAGR of 3.0%. The uptrend in the oil & gas industry, mainly in the upstream sector, growth in the electronics & semiconductor industry and a large number of coal-based power p …
- Practice Management System（医療用情報管理システム）の世界市場（～2018）The Practice management (PM) system offers advanced scheduling, patient registration, medical billing, stores demographic data, claims management, and reporting. The developing markets of Middle East, Australia, New Zealand, China, India, Singapore and Malaysia were identified as high growth markets due to favorable government incentives and developing IT infrastructure In addition, the cloud–base …
- 船用エンジンの世界市場予測（～2021）：出力別、船舶種類別（商用＆海洋支援船）、燃料別、地域別“The marine engines market is projected to grow at a CAGR of 3.85 % from 2016 to 2021” The marine engines market is projected to reach USD 13.53 billion by 2021, growing at a CAGR of 3.85% from 2016 to 2021. Increased demand of commercial vessels and rise in ship-building industry will drive the growth in the marine engines market. A slowdown in the oil & gas industry has been identified as a majo …
- 金属鋳造の世界市場2018-2022About Metal Casting Metals are used in different forms. Metal castings are needed to mold metals into diverse shapes and sizes as per the requirements. Transportation and heavy equipment account for most of the casting products. Metal castings are used for applications like automobiles, aircraft, railways, mining, construction, electrical equipment, oil wells, pipes, space shuttles, wind turbines, …
